论文部分内容阅读
为观察经皮动脉灌注化疗药物及ＬＡＫ／ＩＬ－２治疗晚期贲门癌的疗效，采用经皮穿刺胃左动脉插管灌注健康人外周血ＬＡＫ细胞１×１０８／Ｌ及ＩＬ－２３０万Ｕ，化疗药物为表阿霉素３０ｍｇ、卡铂３００ｍｇ、长春地辛（西艾克）４ｍｇ或５－Ｆｕ１０００ｍｇ，每３周～４周一次，２次为一疗程，结果：经病理学确诊的共７８例晚期贲门癌患者经此法共介入灌注１４６次，最多者５次，最少者１次，胃部病灶ＣＲ＋ＰＲ占６１．５％，生存最长４１个月，最短４个月，中位生存期９．５个月，半年生存率为７６．９％，１年生存率为３０．８％，提示采用肿瘤供血动脉进行区域性灌注生物制剂及化疗药物，对于失去手术机会的晚期贲门癌病人不失为可供选择的有效治疗手段。
In order to observe the efficacy of percutaneous arterial infusion of chemotherapy drugs and LAK/IL-2 in the treatment of advanced cardiac cancer, percutaneous puncture of the left gastric artery was used to perfuse LAK cells in peripheral blood of healthy people 1×108/L and IL-2.3 million U for chemotherapy. The drugs were epirubicin 30 mg, carboplatin 300 mg, vindesine (Si Aik) 4 mg or 5-Fu 1000 mg every 3 weeks to 4 weeks, 2 times for one course of treatment. Results: 78 cases confirmed by pathology The patients with advanced cardial cancer were treated with 146 interventions, the most common ones were 5 times, at least 1 time, CR+PR accounted for 61.5% of the gastric lesions, the longest survival was 41 months, and the shortest 4 months. The median survival time was 9 The five-month and six-year survival rate was 76.9%, and the one-year survival rate was 30.8%, suggesting that regional tumor infusion of biological agents and chemotherapeutic drugs should be used for patients with advanced cardia cancer who have lost surgery. Alternative effective treatments.